Cytosorbents (CTSO) Stock Overview
Engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CTSO Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cytosorbents Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.06 |
| 52 Week High | US$20.40 |
| 52 Week Low | US$5.13 |
| Beta | 1.34 |
| 1 Month Change | -24.23% |
| 3 Month Change | -36.48% |
| 1 Year Change | -66.67% |
| 3 Year Change | -85.29% |
| 5 Year Change | -96.36% |
| Change since IPO | -99.31% |
Recent News & Updates
Narrative Update • Sep 09
CTSO: Reverse Split Plan Will Drive Future Nasdaq Compliance Rebound Potential
Analysts have lifted their price target for Cytosorbents to $47.50 from $5.00, citing updated views on fair value, a slightly higher discount rate, steady revenue growth and profit margin assumptions, and a lower future P/E multiple of 65.88 versus 145.47 in their refreshed models. What’s in the News for Cytosorbents On June 29, 2026, Cytosorbents received a notice from the Nasdaq Listing Qualifications Department that the company did not meet the minimum US$35 million Market Value of Listed Securities requirement for continued listing on the Nasdaq Capital Market.
Narrative Update • Aug 26
CTSO: Reverse Split Authority Will Support Future Listing Compliance Potential
Analysts have reduced their fair value estimate for Cytosorbents stock from $5.00 to $4.00. They cite updated assumptions for the discount rate, revenue growth, profit margin, and future P/E as the main drivers of the new price target.Narrative Update • Aug 11
CTSO: Nasdaq Compliance Deadline And Reverse Split Plan Will Drive Rebound Potential
Analysts have updated their price target for Cytosorbents to $5.00 from $2.88, reflecting revised assumptions around future P/E, revenue growth, and profit margin in their models. What's in the News for Cytosorbents On June 29, 2026, Cytosorbents received a written notice from the Nasdaq Listing Qualifications Department stating that the company was not in compliance with Nasdaq Listing Rule 5550(b)(2) because its Market Value of Listed Securities was below the US$35 million minimum required for continued listing on the Nasdaq Capital Market.Analysis Article • Aug 09
US$2.88: That's What Analysts Think Cytosorbents Corporation (NASDAQ:CTSO) Is Worth After Its Latest Results
Cytosorbents Corporation ( NASDAQ:CTSO ) came out with its quarterly results last week, and we wanted to see how the...Recent updates
Narrative Update • Sep 09
CTSO: Reverse Split Plan Will Drive Future Nasdaq Compliance Rebound Potential
Analysts have lifted their price target for Cytosorbents to $47.50 from $5.00, citing updated views on fair value, a slightly higher discount rate, steady revenue growth and profit margin assumptions, and a lower future P/E multiple of 65.88 versus 145.47 in their refreshed models. What’s in the News for Cytosorbents On June 29, 2026, Cytosorbents received a notice from the Nasdaq Listing Qualifications Department that the company did not meet the minimum US$35 million Market Value of Listed Securities requirement for continued listing on the Nasdaq Capital Market.Narrative Update • Aug 26
CTSO: Reverse Split Authority Will Support Future Listing Compliance Potential
Analysts have reduced their fair value estimate for Cytosorbents stock from $5.00 to $4.00. They cite updated assumptions for the discount rate, revenue growth, profit margin, and future P/E as the main drivers of the new price target.Narrative Update • Aug 11
CTSO: Nasdaq Compliance Deadline And Reverse Split Plan Will Drive Rebound Potential
Analysts have updated their price target for Cytosorbents to $5.00 from $2.88, reflecting revised assumptions around future P/E, revenue growth, and profit margin in their models. What's in the News for Cytosorbents On June 29, 2026, Cytosorbents received a written notice from the Nasdaq Listing Qualifications Department stating that the company was not in compliance with Nasdaq Listing Rule 5550(b)(2) because its Market Value of Listed Securities was below the US$35 million minimum required for continued listing on the Nasdaq Capital Market.Analysis Article • Aug 09
US$2.88: That's What Analysts Think Cytosorbents Corporation (NASDAQ:CTSO) Is Worth After Its Latest Results
Cytosorbents Corporation ( NASDAQ:CTSO ) came out with its quarterly results last week, and we wanted to see how the...Narrative Update • Jun 16
CTSO: Nasdaq Extension And Clinical Data Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Cytosorbents from $10.00 to $5.00, citing updated assumptions that now reflect a higher discount rate, more moderate revenue growth expectations, slightly lower profit margin forecasts, and a modestly lower future P/E multiple. What's in the News Nasdaq granted Cytosorbents a 180 day extension, until September 28, 2026, to regain compliance with the minimum US$1.00 bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2).Narrative Update • Jun 02
CTSO: Nasdaq Compliance Extension Will Support Future Turnaround Potential
Analysts have reduced their fair value estimate for Cytosorbents from $5.00 to $2.88 as they recalibrate assumptions for revenue growth, profit margins, the discount rate, and the stock's future P/E multiple. What's in the News On April 1, 2026, Cytosorbents received a 180 day extension from Nasdaq until September 28, 2026 to regain compliance with the minimum US$1.00 bid price requirement for continued listing.
Narrative Update • May 15
CTSO: ICU Utilization And Nasdaq Compliance Extension Will Support Future Upside
Analysts have kept the fair value estimate for Cytosorbents steady at $0.75. Modest tweaks to assumptions for the discount rate, revenue growth, profit margin, and future P/E reflect updated views on risk, earnings power, and likely valuation multiples.Narrative Update • Apr 27
CTSO: ICU Adoption And Nasdaq Compliance Efforts Will Support Future Upside
Analysts have maintained their $0.75 price target on Cytosorbents. They cite small adjustments in the discount rate, revenue growth assumptions, and future P/E estimates as they refine their models, while keeping their overall valuation view unchanged.Narrative Update • Apr 11
CTSO: 2025 Revenue Outlook And ICU Adoption Will Support Upside
Analysts have maintained their $0.75 price target for Cytosorbents, citing only modest adjustments to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock’s valuation. What's in the News Nasdaq granted CytoSorbents a 180 day extension, until September 28, 2026, to regain compliance with the US$1.00 minimum bid price requirement for continued listing on the exchange, with the stock remaining listed during this period (Delistings notice).Narrative Update • Mar 28
CTSO: Steady 2025 Outlook And ICU Therapy Progress Will Support Upside
Analysts have held their fair value estimate for Cytosorbents steady, keeping the implied price target unchanged at $0.75. This reflects slightly adjusted views on discount rate, revenue growth and profit margin assumptions, without a clear shift in overall conviction.Narrative Update • Mar 12
CTSO: Steady 2025 Revenue Guidance Will Support Measured Long Term Upside
Analysts have made a modest adjustment to their Cytosorbents price target, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Taken together, these changes leave their fair value estimate broadly unchanged around $0.75.Narrative Update • Feb 26
CTSO: Flat 2025 Outlook And Cost Discipline Will Support Measured Upside
Analysts have slightly adjusted their price target for Cytosorbents to reflect updated assumptions around revenue growth, profit margin and future P/E, while keeping the fair value broadly in line at $0.75. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, the same figure as guidance for the fourth quarter of 2024 (Key Developments).Narrative Update • Feb 09
CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Support Upside
Analysts have trimmed their price target on Cytosorbents to reflect a slightly lower assumed discount rate, marginally higher projected revenue growth, improved profit margin expectations, and a modestly lower future P/E multiple. This results in a revised valuation that they see as better aligned with updated assumptions.Narrative Update • Jan 26
CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Shape Outlook
Narrative Update on Cytosorbents Analysts have kept their price target for Cytosorbents steady at US$0.75, citing updated assumptions that reflect slightly lower discount rates, modestly higher projected revenue growth, a stable profit margin outlook, and a small adjustment to expected future P/E levels. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, in line with the fourth quarter of 2024 at US$9.2 million (Key Developments).Narrative Update • Jan 10
CTSO: Cost Reductions And 2026 Cash Flow Break Even Will Support Upside
Analysts have updated their price target on Cytosorbents and maintained fair value at US$0.75. They have also fine tuned underlying assumptions such as the discount rate, revenue growth, profit margin and future P/E to reflect revised views on the company’s risk and earnings profile.Narrative Update • Dec 26
CTSO: Cost Cuts And Nasdaq Listing Risk Will Shape Balanced Outlook
Analysts modestly raised their price target on Cytosorbents to reflect a slightly lower discount rate and higher expected future earnings multiples, even as they tempered long term revenue growth assumptions. What's in the News Cytosorbents announced a strategic workforce and cost reduction plan, cutting approximately 10% of its staff and realigning production and operating expenses to target operating cash flow break even by the first quarter of 2026 (Key Developments).Narrative Update • Dec 12
CTSO: Workforce Cuts And FDA Pathway Are Expected To Shape Outlook
Analysts have trimmed their price target on Cytosorbents from approximately 12.84 dollars to 7.96 dollars. This reflects slightly lower long term revenue growth assumptions, a higher perceived risk profile, and only modestly improved profitability expectations.Analysis Article • Nov 13
Market Cool On Cytosorbents Corporation's (NASDAQ:CTSO) Revenues Pushing Shares 31% Lower
To the annoyance of some shareholders, Cytosorbents Corporation ( NASDAQ:CTSO ) shares are down a considerable 31% in...Analysis Article • Nov 08
Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative Update • Aug 10
FDA And Health Canada Approval Will Spur ICU Solutions
Cytosorbents’ consensus price target has been raised from $5.00 to $7.00, reflecting improved profitability with net profit margin rising to 12.34% and a more attractive future P/E of 74.11x. What's in the News New studies demonstrate early and intensive CytoSorb® therapy significantly improves clinical outcomes for sepsis and septic shock patients, with peer-reviewed data showing increased survival rates when used intensively and early.Analysis Article • Aug 09
Does Cytosorbents (NASDAQ:CTSO) Have A Healthy Balance Sheet?
NasdaqCM:CTSO 1 Year Share Price vs Fair Value Explore Cytosorbents's Fair Values from the Community and select yours...Analysis Article • Jul 02
Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 54% Bounce
Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders would be excited to see that the share price has had a great...
New Narrative • Apr 11
FDA And Health Canada Decisions Will Advance DrugSorb-ATR Launch
Regulatory decisions on DrugSorb-ATR could drive significant revenue growth, especially in the U.S. and Canada, with a large market opportunity.Analysis Article • Jan 17
Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 28% Bounce
Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders are no doubt pleased to see that the share price has bounced 28...Analysis Article • Oct 01
The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More
Despite an already strong run, Cytosorbents Corporation ( NASDAQ:CTSO ) shares have been powering on, with a gain of...Analysis Article • Jul 04
Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)
With a price-to-sales (or "P/S") ratio of 1.3x Cytosorbents Corporation ( NASDAQ:CTSO ) may be sending bullish signals...Analysis Article • Mar 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Shareholder Returns
| CTSO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -11.5% | -3.6% | -1.5% |
| 1Y | -66.7% | -15.8% | 13.3% |
Return vs Industry: CTSO underperformed the US Medical Equipment industry which returned -15.8% over the past year.
Return vs Market: CTSO underperformed the US Market which returned 13.3% over the past year.
Price Volatility
| CTSO volatility | |
|---|---|
| CTSO Average Weekly Movement | 14.9% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CTSO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CTSO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 129 | Phil Chan | www.cytosorbents.com |
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies.
Cytosorbents Corporation Fundamentals Summary
| CTSO fundamental statistics | |
|---|---|
| Market cap | US$19.07m |
| Earnings (TTM) | -US$18.21m |
| Revenue (TTM) | US$37.22m |
0.5x
P/S Ratio-1.0x
P/E RatioIs CTSO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTSO income statement (TTM) | |
|---|---|
| Revenue | US$37.22m |
| Cost of Revenue | US$10.57m |
| Gross Profit | US$26.65m |
| Other Expenses | US$44.86m |
| Earnings | -US$18.21m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.80 |
| Gross Margin | 71.61% |
| Net Profit Margin | -48.94% |
| Debt/Equity Ratio | -2,295.7% |
How did CTSO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/15 21:59 |
| End of Day Share Price | 2026/09/15 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytosorbents Corporation is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sean Lee | H.C. Wainwright & Co. |
| Anthony Petrone | Jefferies LLC |
| Danielle Antalffy | Leerink Partners LLC |